Skip to content

Laëtitia Bénard

Partner

Paris

Benard Laetitia
Laëtitia Bénard

Partner

Paris

Laëtitia leads the Paris Intellectual Property practice and is co-head of Allen & Overy's Life Sciences Group worldwide. Laëtitia is a litigator specializing in domestic and cross-border patent litigation.

She has a wealth of expertise in all intellectual property areas, more particularly having acted in numerous complex patent disputes involving pharmaceutical and high tech companies. She also advises on patent portfolios, patent validity, and freedom to operate issues. She has specific knowledge of the life sciences field, in which she also advises on various regulatory and contractual matters such as price regulation, advertisement for medicines, transfers of technology and anti-bribery rules. 
Laëtitia frequently publishes on life sciences regulatory topics and has written a number of clients alerts on issues such as biosimilars, the-EFPIA-Transparency-Initiative, and the online sale of medicines. Her publications include "Interim injunctions over patents – The French practice" in Managing Intellectual Property (February 2013); "Overview of Life Sciences law in France" in Chambers Life Sciences Guide 2013; "Why France is a good forum for preliminary injunctions in patent matters" in Global Business Magazine, 2012; "Supplementary Protection Certificates – CJEU provides welcome clarifications" International Who's Who Legal - Life Sciences, 2012; "Preliminary injunctions in Europe: an overview in the field of patents", The Handbook of European IP Management, 2012.

Laëtitia is a recognised practitioner by « Best Lawyers » since 2013 in Biotechnology and Life Sciences Practice and Intellectual Property Law"

Life Sciences Firm of the Year (France)
LMG Life Sciences Awards Europe 2020

"Very strong in pharma proceedings"
Juve – France 2020 

"Leading Individual"
Legal 500 EMEA 2020 – France (INTELLECTUAL PROPERTY: PATENTS)

"Laëtitia Bénard, the doyenne of life sciences litigation on behalf of originators, displays bulldog determination to win. She is a real fighter, creative, superb in court, producer of erudite submissions and a delight to work with." 
Legal 500 EMEA 2020 – France (INTELLECTUAL PROPERTY: PATENTS)

"Laëtitia Bénard, with her team, is very experienced, in particular in patent/SPC matters in the pharmaceutical field. Respected, client-oriented, responsive, creative, pragmatic." 
Legal 500 EMEA 2020 – France (INTELLECTUAL PROPERTY: PATENTS)

"Leading Individual"
Legal 500 EMEA 2020 – France (HEALTHCARE & LIFE SCIENCES)

"Laëtitia Bénard works tirelessly. She has knowledge of pharmaceutical law, and also of biotech and computer law." 
Legal 500 EMEA 2020 – France (HEALTHCARE & LIFE SCIENCES)
 
"Laëtitia Bénard, who co-heads the firm's life sciences group worldwide, is second to none in patent litigation." 
Legal 500 EMEA 2020 – France (HEALTHCARE & LIFE SCIENCES)

Laëtitia Bénard ranked Silver for Enforcement and Litigation, as well as Prosecution and Strategy 
WTR1000 2020

Band 1
Chambers Global/Europe 2020 - France (Intellectual Property)

The "fantastic" Laëtitia Bénard regularly acts for high-profile clients from the pharmaceutical industry on contentious patent mandates. She draws high praise from clients, one of whom states: "She is a top IP lawyer in the pharmaceutical world. She is determined, hard-working and a superb advocate." 
Chambers Global/Europe 2020 - France (Intellectual Property)

Band 1
Chambers Global/Europe 2020 - France (Pharma/Life Sciences: Intellectually Property)

The "extremely talented" Laëtitia Bénard is renowned as a patent litigator, most notably acting for high-profile pharmaceutical companies. One source says she is "very knowledgeable," before going on to add that she has a "very good grasp of IP enforcement in France." 
Chambers Global/Europe 2020 - France (Pharma/Life Sciences: Intellectually Property)

Leader
IAM Global Leaders Guide 2020

Global leader in Patents 
Who's Who Legal 2020

"Litigator Laëtitia Bénard heads both the IP practice in Paris and Allen & Overy’s life sciences group globally, gathering plaudits from the market for her finely tuned high-tech and pharmaceutical advice." 
IAM Patent 1000 2019 - France

Laëtitia Bénard - Ranked Gold in Litigation 
IAM Patent 1000 2019 - France

Global Leader in Life Sciences - Patent Litigation 2019, Patents 2019 and National Leader France - Life Sciences, France - Patents 
Who's Who Legal 2019

Silver for enforcement and litigation; prosecution and strategy 
WTR 1000- 2018-2019

Leading Individual 
LEGAL 500 EMEA 2018-2019 – France (Intellectual Property: Patents)

"Best in Patent" 
Euromoney LMG Europe Women in Business Law Awards 2019

"Intellectual Property Lawyer of the Year" 
Benchmark Litigation Europe 2019

"Laëtitia Bénard specialises in pharmaceutical patent litigation and is lauded as "an excellent lawyer for contentious matters." Another source enthuses: "She is famous for being a hard-working, excellent lawyer for patent matters," adding: "She is a determined and effective presence in court."" 
Chambers 2019 - France (Pharma/Life Sciences)

"Laëtitia Bénard is a market leader in IP and primarily acts on patent litigation cases for pharmaceutical companies. She is highly respected by clients and peers who highlight her client dedication and industry knowledge. She assisted Pfizer with a patent litigation case concerning the validity of a second medical use patent." 
Chambers 2019 - France (Intellectual Property)

"Leading Life sciences practitioner in France." 
Euromoney Expert Guides: Best of the Best Global Awards 2019

"Litigation Star for IP Litigation in France " 
Benchmark Europe 2019

“IP Star” and “Top 250 Woman in IP”
Managing IP – Patents and Trademark 2018

“Laëtitia Bénard is described by clients as "very impressive" and "very knowledgeable about the pharmaceutical industry as a whole." She is further praised for her cross-border capabilities and her "pragmatic and result-oriented" nature.” 
Chambers Europe 2018 - France (Pharma/Life Sciences)

“Laëtitia Bénard is head of the firm's Paris IP practice. Clients say: "She is able to grasp complex issues and thinks about the big picture.” 
Chambers Europe 2018 - France (Intellectual Property)

"Peers shower Bénard with praise: ‘She’s an extremely hard worker with a tremendous reputation. Her importance in the IP scene is unquestionable.’.” 
IAM Patent 1000 2018 - France

“Pharmaceuticals powerhouse Bénard’s extremely impressive in court and has a strong understanding of procedural issues.” 
WTR 1000 2018

"Laëtitia is managing the team well," says a market commentator. According to one client, Bénard is "highly skilled in litigation". Another client adds: "Laëtitia is the go-to lawyer for life sciences companies and her skills are second to none."
Managing IP Europe 2018

Laëtitia Bénard heads the IP and litigation department: "She is incredibly capable, knows her cases extremely well, anticipates questions before they arise and has a complete grasp of all aspects of IP litigation issues in France". 
IAM Patent 1000 2017 - France

"Practice head Laëtitia Bénard is ‘very impressive and the must-use lawyer in the life sciences area’." 
Legal 500 EMEA 2017 – France (Intellectual Property: Patents)

"Laëtitia Bénard excels in all aspects of IP with a particular focus on the life sciences sector." 
Chambers Europe 2017 - France (Intellectual Property)

"Laëtitia Bénard is described as a 'very present and important' practitioner in the market. She has particular expertise in the life sciences sector." 
Who's Who Legal 2017 - France

News & insights

News: 03 JULY 2020

Addressing climate change with the Jane Goodall Institute

To mark the first part of London Climate Action Week, we look at the work being done by teams in Belgium, Hong Kong, London and Australia to support the Jane Goodall Institute – a global conservation…

Read more
Key regulatory topics

Publications: 02 JULY 2020

Key Regulatory Topics: Weekly update 19 – 25 June 2020

Our weekly update on key regulatory topics affecting the financial services sector. If you would like to receive this update by email and be added to our marketing mailing list please contact…

Read more
Key regulatory topics

Publications: 02 JULY 2020

CMA calls for new UK regulatory regime for online platforms to address market study concerns

On 1 July the UK Competition and Markets Authority (CMA) released the final report in its year-long market study into online platforms and digital advertising, finding a number of concerns over the…

Read more

Publications: 30 JUNE 2020

Beyond Covid-19: Emerging market private equity driving growth

This timely discussion is part of a series of Allen & Overy conversations with senior industry players to explore opportunities for recovery and growth.

Read more

Office

Paris

Allen & Overy LLP
52 avenue Hoche
75008 Paris

View office →

Qualifications

Professional

Admitted to the Bar, Paris, 2000

Academic

Post Graduate Degree, Industrial Property, University of Paris II Panthéon Assas, 1999

Post Graduate Degree, French Civil Law, University of Paris I Panthéon Sorbonne, 1998

Pro-bono experience

  • Advising French non-profit organisation "Autistes Sans Frontières" ("Autistics Without Borders")

 

Published work

  • ‘Brexit’: time is of the essence for life sciences innovators – LSIPR (Life Sciences Intellectual Property Review) – June 2016
  • La juridiction unifiée du brevet (JUB) : un atout indéniable pour l'Europe, La Lettre des juristes d'affaires, July 2014
  • La juridiction unifiée du brevet (JUB) reçoit un soutien croissant des entreprises, Option Droit et Finance, July 2014 co-authored with David Por
  • France’s Biosimilar law may set trend inside the EU, Law 360, February 2014, co-authored with Eveline Van Keymeulen
  • L’Acte II de l’exception culturelle sur la scène du numérique, Les Echos, June 2013
  • "France" chapter, International Copyright Law book, Global Law & Business, May 2013, co-authored with Alexandre Rudoni and Olivia Klimis
  • Overview of Life Sciences law in France, Chambers Life Sciences Guide 2013, co-authored with Olivier Fréget, David Por and Olivia Klimis
  • Interim injunctions over patents, The French practice, Managing Intellectual Property, co-authored with Olivia Klimis
  • Choisir la stratégie juridique adéquate pour valoriser sa marque - Décryptage avec Laëtitia Bénard, Les Echos, December 2012
  • Comparative Advertising for generics in Germany and France after L’Oréal v Bellure, PTMG Law Lore & Practice, December 2012, co-authored with Oscar Benito, Rainer Kaase and Ralf Möller
  • Il faut sauver le projet de brevet unitaire européen, Option Droit & Affaires, September 2012, co-authored with Olivia Klimis
  • Preliminary injunctions in Europe: an overview in the field of patents, The Handbook of European IP Management, May 2012
  • Trade secrets protection: a comparative overview, The Handbook of European IP Management, May 2012, co-authored with  Benjamin Bai and Paul B. Keller
  • Why France is a good forum for preliminary injunctions in patent matters, Global Business Magazine, April 2012
  • Supplementatry protection certificates: CJEU provides welcome clarifications, Who's Who Legal, Life Sciences, April 2012, co-authored with Olivia Klimis
  • Trade secrets protection, Commerce International, April 2012
  • L'arrêt DHL/Chronopost de la CJUE du 12 avril 2011 : une injonction communautaire peut être obtenue dans les limites de l'atteinte aux fonctions de la marque, Revue Lamy Droit de l'immatériel, August/September 2011, co-authored with Alexandra Abello
  • Competition, Public Health, Innovation and Drugs, LGDJ, 2010, under the supervision of Marie-Anne Frison-Roche
  • Generic drugs and IP law, Lamy Droit de la Santé, 2002, 2004 and 2008
  • Question 202 of the AIPPI French group on "The impact of public health issues on exclusive patents rights", September 2008
  • The DADVSI law regarding television: three steps backward for right owners?, Legipresse, May 2007, co-authored with Alexandre Rudoni
  • Rights owners and users fail to agree on reform, Managing Intellectual Property, June 2006, co-authored with Alexandre Rudoni
  • How to prepare the businessmen in the biotechnology sector for the cession of their firm, Bio Futur, October 2005, co-authored with Alexandre Rudoni